| Thomas Kayani, MD | |
|
411 E Market St, Akron, OH 44304-1542 | |
| (330) 252-0600 | |
| (330) 252-0700 |
| Full Name | Thomas Kayani |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 28 Years |
| Location | 411 E Market St, Akron, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912909839 | NPI | - | NPPES |
| 2248320 | Medicaid | OH | |
| 390007541 | Other | OH | RR MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 35079414K (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Davita Akron Renal Center | Akron, OH | Dialysis facility |
| Davita - Summit Renal Care | Akron, OH | Dialysis facility |
| Summa Health System | Akron, OH | Hospital |
| Akron General Medical Center | Akron, OH | Hospital |
| Western Reserve Hospital | Cuyahoga falls, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northeast Ohio Nephrology Associates Inc | 8325028418 | 6 |
News Archive
New clinical data presented today at EuroPCR demonstrate positive long-term performance and durability for the CoreValve transcatheter aortic valve replacement system from Medtronic, Inc. Two-year results from the pivotal 18-French CoreValve multicenter prospective study provide important additional evidence supporting wider use of the world's market-leading transcatheter aortic valve.
They make up less than one-hundredth of 1 percent of the microbes that live in the colon, but the bacteria and archaea that sop up hydrogen in the gut are fundamental to colon health. In a new study, researchers take a first look at these "hydrogenotrophic" microbes, mapping where they live and how abundant they are in different parts of the lower intestine.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced data from a subgroup analysis of a Phase 2 randomized discontinuation trial showing that the median progression-free survival (PFS) achieved by patients with advanced clear cell renal cell carcinoma (RCC) who had undergone a prior nephrectomy was 14.8 months.
A new study presages a real aim of genetics: to look at whole populations to in order determine the significance of individual genetic variants for individual health. The research team, whose work is published in Nature Genetics, find six novel genetic variants that are associated with lipid levels, a common indicator of heart or artery disease.
› Verified 7 days ago
| Entity Name | Northeast Ohio Nephrology Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356459481 PECOS PAC ID: 8325028418 Enrollment ID: O20040720001675 |
News Archive
New clinical data presented today at EuroPCR demonstrate positive long-term performance and durability for the CoreValve transcatheter aortic valve replacement system from Medtronic, Inc. Two-year results from the pivotal 18-French CoreValve multicenter prospective study provide important additional evidence supporting wider use of the world's market-leading transcatheter aortic valve.
They make up less than one-hundredth of 1 percent of the microbes that live in the colon, but the bacteria and archaea that sop up hydrogen in the gut are fundamental to colon health. In a new study, researchers take a first look at these "hydrogenotrophic" microbes, mapping where they live and how abundant they are in different parts of the lower intestine.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced data from a subgroup analysis of a Phase 2 randomized discontinuation trial showing that the median progression-free survival (PFS) achieved by patients with advanced clear cell renal cell carcinoma (RCC) who had undergone a prior nephrectomy was 14.8 months.
A new study presages a real aim of genetics: to look at whole populations to in order determine the significance of individual genetic variants for individual health. The research team, whose work is published in Nature Genetics, find six novel genetic variants that are associated with lipid levels, a common indicator of heart or artery disease.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Thomas Kayani, MD 411 E Market St, Akron, OH 44304-1542 Ph: (330) 252-0600 | Thomas Kayani, MD 411 E Market St, Akron, OH 44304-1542 Ph: (330) 252-0600 |
News Archive
New clinical data presented today at EuroPCR demonstrate positive long-term performance and durability for the CoreValve transcatheter aortic valve replacement system from Medtronic, Inc. Two-year results from the pivotal 18-French CoreValve multicenter prospective study provide important additional evidence supporting wider use of the world's market-leading transcatheter aortic valve.
They make up less than one-hundredth of 1 percent of the microbes that live in the colon, but the bacteria and archaea that sop up hydrogen in the gut are fundamental to colon health. In a new study, researchers take a first look at these "hydrogenotrophic" microbes, mapping where they live and how abundant they are in different parts of the lower intestine.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced data from a subgroup analysis of a Phase 2 randomized discontinuation trial showing that the median progression-free survival (PFS) achieved by patients with advanced clear cell renal cell carcinoma (RCC) who had undergone a prior nephrectomy was 14.8 months.
A new study presages a real aim of genetics: to look at whole populations to in order determine the significance of individual genetic variants for individual health. The research team, whose work is published in Nature Genetics, find six novel genetic variants that are associated with lipid levels, a common indicator of heart or artery disease.
› Verified 7 days ago
Dr. Michael A Pelini, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 95 Arch St, Ste 300, Akron, OH 44304 Phone: 330-376-7000 Fax: 330-376-1066 | |
David P. Lang, M.D. Nephrology Medicare: Not Enrolled in Medicare Practice Location: 4125 Medina Rd, #200c, Akron, OH 44333 Phone: 330-665-8031 Fax: 330-665-8360 | |
Ms. Tiffany Mccann, D.O. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 525 E Market St, Akron, OH 44304 Phone: 330-375-3561 | |
Jonathan Buggey, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 95 Arch St Ste 300, Akron, OH 44304 Phone: 724-422-6808 | |
Shamsa Baaj, MD Nephrology Medicare: Medicare Enrolled Practice Location: 1 Akron General Ave, Akron, OH 44307 Phone: 330-344-6000 | |
Mira Rohit Patel, DO Nephrology Medicare: Medicare Enrolled Practice Location: 161 N Forge St Ste 198, Akron, OH 44304 Phone: 330-375-3039 | |
Richard J Streck, MD Nephrology Medicare: Not Enrolled in Medicare Practice Location: 400 Wabash Ave, 5th Floor Ambulatory Care Center, Akron, OH 44307 Phone: 330-344-6015 Fax: 330-344-6820 |